View Future GrowthCryosite 過去の業績過去 基準チェック /36Cryositeは、平均年間20.8%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間 成長しています。収益は、平均年間1.6% 8%収益成長率で 成長しています。 Cryositeの自己資本利益率は60.5%であり、純利益率は13.9%です。主要情報20.76%収益成長率20.29%EPS成長率Life Sciences 業界の成長19.72%収益成長率8.01%株主資本利益率60.52%ネット・マージン13.87%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 03First half 2026 earnings released: EPS: AU$0.023 (vs AU$0.017 in 1H 2025)First half 2026 results: EPS: AU$0.023 (up from AU$0.017 in 1H 2025). Revenue: AU$8.27m (up 25% from 1H 2025). Net income: AU$1.14m (up 36% from 1H 2025). Profit margin: 14% (up from 13% in 1H 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year.Reported Earnings • Aug 22Full year 2025 earnings released: EPS: AU$0.039 (vs AU$0.038 in FY 2024)Full year 2025 results: EPS: AU$0.039 (up from AU$0.038 in FY 2024). Revenue: AU$14.1m (up 12% from FY 2024). Net income: AU$1.88m (up 2.4% from FY 2024). Profit margin: 13% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 24First half 2025 earnings released: EPS: AU$0.017 (vs AU$0.017 in 1H 2024)First half 2025 results: EPS: AU$0.017 (in line with 1H 2024). Revenue: AU$6.64m (up 3.7% from 1H 2024). Net income: AU$838.0k (flat on 1H 2024). Profit margin: 13% (in line with 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 21Full year 2024 earnings released: EPS: AU$0.038 (vs AU$0.029 in FY 2023)Full year 2024 results: EPS: AU$0.038 (up from AU$0.029 in FY 2023). Revenue: AU$12.6m (up 5.7% from FY 2023). Net income: AU$1.84m (up 31% from FY 2023). Profit margin: 15% (up from 12% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year.Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0.014 (vs AU$0.016 in 1H 2022)First half 2023 results: EPS: AU$0.014 (down from AU$0.016 in 1H 2022). Revenue: AU$5.72m (down 1.7% from 1H 2022). Net income: AU$678.7k (down 13% from 1H 2022). Profit margin: 12% (down from 13% in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 150% per year, which means it is well ahead of earnings.Reported Earnings • Aug 26Full year 2022 earnings released: EPS: AU$0.028 (vs AU$0.014 in FY 2021)Full year 2022 results: EPS: AU$0.028 (up from AU$0.014 in FY 2021). Revenue: AU$11.8m (up 17% from FY 2021). Net income: AU$1.36m (up 109% from FY 2021). Profit margin: 12% (up from 6.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 136% per year, which means it is tracking significantly ahead of earnings growth.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 18%After last week's 18% share price gain to AU$1.25, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 36x in the Life Sciences industry globally. Total returns to shareholders of 128% over the past three years.分析記事 • Jun 01Cryosite (ASX:CTE) Ticks All The Boxes When It Comes To Earnings GrowthFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • Mar 03First half 2026 earnings released: EPS: AU$0.023 (vs AU$0.017 in 1H 2025)First half 2026 results: EPS: AU$0.023 (up from AU$0.017 in 1H 2025). Revenue: AU$8.27m (up 25% from 1H 2025). Net income: AU$1.14m (up 36% from 1H 2025). Profit margin: 14% (up from 13% in 1H 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year.New Risk • Feb 28New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 114% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (114% net debt to equity). Market cap is less than US$100m (AU$58.8m market cap, or US$41.9m).分析記事 • Feb 09Cryosite Limited's (ASX:CTE) Price Is Out Of Tune With EarningsWith a price-to-earnings (or "P/E") ratio of 31.2x Cryosite Limited ( ASX:CTE ) may be sending very bearish signals at...Board Change • Jan 13No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Dec 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Valuation Update With 7 Day Price Move • Oct 27Investor sentiment improves as stock rises 28%After last week's 28% share price gain to AU$1.30, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 36x in the Life Sciences industry globally. Total returns to shareholders of 125% over the past three years.Board Change • Sep 18No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Aug 22Full year 2025 earnings released: EPS: AU$0.039 (vs AU$0.038 in FY 2024)Full year 2025 results: EPS: AU$0.039 (up from AU$0.038 in FY 2024). Revenue: AU$14.1m (up 12% from FY 2024). Net income: AU$1.88m (up 2.4% from FY 2024). Profit margin: 13% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.分析記事 • Aug 19Cryosite Limited's (ASX:CTE) Share Price Could Signal Some RiskASX:CTE 1 Year Share Price vs Fair Value Explore Cryosite's Fair Values from the Community and select yours It's not a...お知らせ • Aug 18Cryosite Limited, Annual General Meeting, Oct 16, 2025Cryosite Limited, Annual General Meeting, Oct 16, 2025. Location: at the thomson geer offices, at level 23, rialto south tower, 525 collins street, melbourne vic 3004 AustraliaRecent Insider Transactions • Jul 02Non-Executive Chairman recently bought AU$56k worth of stockOn the 27th of June, Mark Kerr bought around 75k shares on-market at roughly AU$0.74 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Mark's only on-market trade for the last 12 months.Board Change • Jun 23No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Mar 17No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Feb 24First half 2025 earnings released: EPS: AU$0.017 (vs AU$0.017 in 1H 2024)First half 2025 results: EPS: AU$0.017 (in line with 1H 2024). Revenue: AU$6.64m (up 3.7% from 1H 2024). Net income: AU$838.0k (flat on 1H 2024). Profit margin: 13% (in line with 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jan 15Cryosite Limited's (ASX:CTE) Subdued P/E Might Signal An OpportunityThere wouldn't be many who think Cryosite Limited's ( ASX:CTE ) price-to-earnings (or "P/E") ratio of 19.1x is worth a...お知らせ • Nov 22Cryosite Limited Announces Resignation of Michael Austin as Joint Company SecretaryCryosite Limited announced that Mr. Michael Austin has resigned as Joint Company Secretary, effective 22 November 2024. Mr. Hamish George of Bio101 Financial Advisory Pty Ltd. remains as Company Secretary and is responsible for communications with the ASX in relation to Listing Rule matters under ASX Listing Rule 12.6.お知らせ • Oct 21Cryosite Limited, Annual General Meeting, Nov 22, 2024Cryosite Limited, Annual General Meeting, Nov 22, 2024. Location: boardroom, level 2 90 william st, melbourne,vic, 3000., melbourne, Australiaお知らせ • Sep 20Cryosite Limited Announces Company Secretary ChangesCryosite Limited announced that Hamish George and Michael Austin of Bio101 Financial Advisory Pty Ltd. (Bio101) have been appointed Joint Company Secretaries of the Company. The appointment follows the resignation of Mr. Dray Andrea as Company Secretary, effective 20 September 2024. The Board would like to thank Mr. Andrea for his service in the role of Company Secretary.分析記事 • Aug 22Cryosite (ASX:CTE) Is Due To Pay A Dividend Of A$0.02Cryosite Limited ( ASX:CTE ) has announced that it will pay a dividend of A$0.02 per share on the 10th of October. This...Declared Dividend • Aug 22Final dividend of AU$0.02 announcedShareholders will receive a dividend of AU$0.02. Ex-date: 6th September 2024 Payment date: 10th October 2024 Dividend yield will be 8.8%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 14% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • Aug 21Full year 2024 earnings released: EPS: AU$0.038 (vs AU$0.029 in FY 2023)Full year 2024 results: EPS: AU$0.038 (up from AU$0.029 in FY 2023). Revenue: AU$12.6m (up 5.7% from FY 2023). Net income: AU$1.84m (up 31% from FY 2023). Profit margin: 15% (up from 12% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year.分析記事 • Aug 20With A 31% Price Drop For Cryosite Limited (ASX:CTE) You'll Still Get What You Pay ForCryosite Limited ( ASX:CTE ) shares have had a horrible month, losing 31% after a relatively good period beforehand...お知らせ • Aug 20+ 2 more updatesCryosite Limited Announces Retirement of John Hogg as Chief Executive Officer, Effective October 31, 2024Cryosite announced the retirement of its Chief Executive Officer, Mr. John Hogg, with effect from October 31, 2024. The Board thanks Mr. Hogg for his support and service to the Board and the Company over his tenure.Buy Or Sell Opportunity • Jul 26Now 20% undervaluedOver the last 90 days, the stock has risen 14% to AU$0.97. The fair value is estimated to be AU$1.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.5% over the last 3 years. Earnings per share has grown by 29%.分析記事 • Jul 23Calculating The Intrinsic Value Of Cryosite Limited (ASX:CTE)Key Insights The projected fair value for Cryosite is AU$1.21 based on 2 Stage Free Cash Flow to Equity With AU$0.98...New Risk • Jun 26New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: AU$8.2m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Significant insider selling over the past 3 months (AU$8.2m sold). Market cap is less than US$100m (AU$56.1m market cap, or US$37.5m).お知らせ • Jun 25Cryosite Limited Announces Retirement of Andrew Kroger from the Board of DirectorsCryosite Limited announced that Andrew Kroger has retired from the board of directors (Board) effective from June 25, 2024.Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 24%After last week's 24% share price gain to AU$1.05, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 32x in the Life Sciences industry globally. Total returns to shareholders of 238% over the past three years.分析記事 • May 09Cryosite Limited's (ASX:CTE) 33% Jump Shows Its Popularity With InvestorsThe Cryosite Limited ( ASX:CTE ) share price has done very well over the last month, posting an excellent gain of 33...Recent Insider Transactions • Apr 27Non Executive Director recently sold AU$830k worth of stockOn the 23rd of April, Andrew Kroger sold around 1m shares on-market at roughly AU$0.83 per share. This transaction amounted to 7.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • Feb 22Cryosite Limited Announces Board ChangesCryosite Limited announced the appointment of Mr. Andrew Kerr as a Director of the Company. Mr. John Hogg will step down as Managing Director and continue in his current executive position as CEO of Cryosite. Andrew is an experienced financial services professional in both the Australian and international markets. Andrew is a qualified Certified Practising Accountant (CPA) and a graduate of the Australian Institute of Company Directors (GAICD) course. Through his roles at Bank of America Merrill Lynch and Macquarie Bank, Andrew has obtained strong sustainability and ESG credentials which will greatly complement the Board.Upcoming Dividend • Feb 14Upcoming dividend of AU$0.05 per share at 2.2% yieldEligible shareholders must have bought the stock before 21 February 2024. Payment date: 29 February 2024. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Australian dividend payers (6.5%). Higher than average of industry peers (0.5%).分析記事 • Feb 02Subdued Growth No Barrier To Cryosite Limited's (ASX:CTE) PriceWhen close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Board Change • Dec 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Chairman Mark Kerr was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 08Cryosite Limited Announces Director ChangesCryosite Limited announced the appointment of Mr. Mark Kerr, as a new Director and Chairman. Mr. John Hogg, CEO of Cryosite will also join the Board as the Managing Director. The only variation to Mr. Hogg's employment agreement is to reflect his new office with the Company. The company announced the retirement from the Board of Directors of Steven Waller, Nicola Swift and Luis Antonio. The Board thanks the three retiring directors for their outstanding contribution to the Company over a number of years. The retiring directors have contributed substantial hours beyond what was expected to ensure the success of the Company going forward.お知らせ • Oct 02Cryosite Limited, Annual General Meeting, Nov 23, 2023Cryosite Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time. Location: The offices of Cryosite, 13A Ferndell St, South Granville New South Wales AustraliaUpcoming Dividend • Aug 31Upcoming dividend of AU$0.015 per share at 1.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 06 October 2023. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Australian dividend payers (7.0%). Higher than average of industry peers (0.5%).お知らせ • Aug 25Cryosite Limited Announces Dividend for the Twelve Months Ended June 30, 2023, Payable on October 6, 2023Cryosite Limited announced dividend of AUD 0.01500000 per share for the twelve months ended June 30, 2023. Record date is September 8, 2023. Ex-date is September 7, 2023. Payment date is October 6, 2023.Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0.014 (vs AU$0.016 in 1H 2022)First half 2023 results: EPS: AU$0.014 (down from AU$0.016 in 1H 2022). Revenue: AU$5.72m (down 1.7% from 1H 2022). Net income: AU$678.7k (down 13% from 1H 2022). Profit margin: 12% (down from 13% in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 150% per year, which means it is well ahead of earnings.分析記事 • Feb 07Do Cryosite's (ASX:CTE) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...お知らせ • Jan 20Cryosite Limited Announces Change of Company SecretaryCryosite Limited announces the resignation of Kim Bradley-Ware and the appointment of Dray Andrea as Company Secretary, both effective January 18, 2023.Recent Insider Transactions • Jan 18Insider recently bought AU$481k worth of stockOn the 13th of January, Mark Kerr bought around 650k shares on-market at roughly AU$0.74 per share. This transaction amounted to 39% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$582k. Insiders have collectively bought AU$2.6m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Dec 26Insider recently bought AU$582k worth of stockOn the 19th of December, Mark Kerr bought around 885k shares on-market at roughly AU$0.66 per share. This transaction amounted to 79% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$2.1m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Oct 14Insider recently bought AU$447k worth of stockOn the 11th of October, Mark Kerr bought around 600k shares on-market at roughly AU$0.74 per share. This transaction amounted to 63% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$1.6m more in shares than they have sold in the last 12 months.お知らせ • Sep 21Cryosite Limited, Annual General Meeting, Nov 17, 2022Cryosite Limited, Annual General Meeting, Nov 17, 2022, at 10:00 E. Australia Standard Time. Location: at the offices of Stone & Chalk, Level 4, 11 York Street, Sydney NSW 2000 Sydney Nsw 2000 AustraliaUpcoming Dividend • Sep 08Upcoming dividend of AU$0.01 per shareEligible shareholders must have bought the stock before 15 September 2022. Payment date: 14 October 2022. Trailing yield: 1.4%. Lower than top quartile of Australian dividend payers (6.6%). Higher than average of industry peers (0.4%).お知らせ • Aug 26Cryosite Limited Announces Ordinary Dividend for the Year Ended June 30, 2022, Payable on October 14, 2022Cryosite Limited announced ordinary dividend of AUD 0.01000000 for the year ended June 30, 2022. Record Date is September 16, 2022. Ex Date is September 15, 2022. Payment Date is October 14, 2022.Reported Earnings • Aug 26Full year 2022 earnings released: EPS: AU$0.028 (vs AU$0.014 in FY 2021)Full year 2022 results: EPS: AU$0.028 (up from AU$0.014 in FY 2021). Revenue: AU$11.8m (up 17% from FY 2021). Net income: AU$1.36m (up 109% from FY 2021). Profit margin: 12% (up from 6.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 136% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Aug 19Should You Be Adding Cryosite (ASX:CTE) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • May 02Do Cryosite's (ASX:CTE) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Nicola Swift was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Mar 03Non Executive Director recently bought AU$321k worth of stockOn the 28th of February, Andrew Kroger bought around 716k shares on-market at roughly AU$0.45 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$931k more in shares than they have sold in the last 12 months.Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: AU$0.016 (up from AU$0.006 in 1H 2021). Revenue: AU$5.82m (up 19% from 1H 2021). Net income: AU$782.4k (up 175% from 1H 2021). Profit margin: 13% (up from 5.8% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 119% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions Derivative • Sep 09Key Executive exercised options to buy AU$546k worth of stock.On the 6th of September, Bryan Dulhunty exercised options to buy 1m shares at a strike price of around AU$0.06, costing a total of AU$78k. This transaction amounted to 4,333% of their direct individual holding at the time of the trade. Bryan currently holds less than 1% of total shares outstanding. Company insiders have collectively bought AU$687k more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Aug 26Full year 2021 earnings released: EPS AU$0.014 (vs AU$0.032 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: AU$10.1m (up 12% from FY 2020). Net income: AU$652.6k (down 56% from FY 2020). Profit margin: 6.5% (down from 17% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Jun 11Non Executive Director recently bought AU$170k worth of stockOn the 8th of June, Andrew Kroger bought around 473k shares on-market at roughly AU$0.36 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$173k more in shares than they have sold in the last 12 months.Is New 90 Day High Low • Feb 17New 90-day low: AU$0.21The company is down 25% from its price of AU$0.28 on 18 November 2020. The Australian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period.Is New 90 Day High Low • Dec 21New 90-day high: AU$0.36The company is up 59% from its price of AU$0.23 on 22 September 2020. The Australian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 2.0% over the same period.Is New 90 Day High Low • Nov 12New 90-day high: AU$0.30The company is up 76% from its price of AU$0.17 on 14 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.お知らせ • Oct 15+ 1 more updateCryosite Limited Announces the Appointment of John Hogg as Chief Executive OfficerCryosite Limited announced the appointment of Mr. John Hogg as Chief Executive Officer of the Company commencing October 15, 2020. Mr. Hogg joined Cryosite in July 2018 and was promoted to General Manager of Operations on the December 1, 2019. He has deployed his skills and experience in Australia, Asia and the US. Mr. Hogg has qualifications in materials management, freight management, accounting and computing, including European Senior Logistician (ESLog) certification, and he is a Chartered Member of The Chartered Institute of Logistics and Transport (CMILT).Is New 90 Day High Low • Oct 08New 90-day high: AU$0.24The company is up 71% from its price of AU$0.14 on 10 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 2.0% over the same period.Is New 90 Day High Low • Sep 18New 90-day high: AU$0.21The company is up 65% from its price of AU$0.13 on 18 June 2020. The Australian market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 11% over the same period.収支内訳Cryosite の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史ASX:CTE 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 251626030 Sep 251526030 Jun 251426031 Mar 251325031 Dec 241325030 Sep 241325030 Jun 241325031 Mar 241325031 Dec 231325030 Sep 231215030 Jun 231215031 Mar 231215031 Dec 221215030 Sep 221215030 Jun 221214031 Mar 221114031 Dec 211114030 Sep 211014030 Jun 211014031 Mar 211014031 Dec 201015030 Sep 20915030 Jun 20914031 Mar 20924031 Dec 19823030 Sep 19813030 Jun 198-13031 Dec 187-23030 Sep 186-13030 Jun 18603031 Dec 17603030 Sep 17603030 Jun 17603031 Mar 17703031 Dec 16803030 Sep 16903030 Jun 161004031 Mar 161004031 Dec 15904030 Sep 1510040質の高い収益: CTEは 高品質の収益 を持っています。利益率の向上: CTEの現在の純利益率 (13.9%)は、昨年(14.3%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CTEの収益は過去 5 年間で年間20.8%増加しました。成長の加速: CTEの過去 1 年間の収益成長率 ( 19.2% ) は、5 年間の平均 ( 年間20.8%を下回っています。収益対業界: CTEの過去 1 年間の収益成長率 ( 19.2% ) はLife Sciences業界14.1%を上回りました。株主資本利益率高いROE: CTEの 自己資本利益率 ( 60.52% ) は 抜群 ですが、負債レベルが高いためこの指標は歪んでいます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/05 10:16終値2026/07/21 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cryosite Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 03First half 2026 earnings released: EPS: AU$0.023 (vs AU$0.017 in 1H 2025)First half 2026 results: EPS: AU$0.023 (up from AU$0.017 in 1H 2025). Revenue: AU$8.27m (up 25% from 1H 2025). Net income: AU$1.14m (up 36% from 1H 2025). Profit margin: 14% (up from 13% in 1H 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year.
Reported Earnings • Aug 22Full year 2025 earnings released: EPS: AU$0.039 (vs AU$0.038 in FY 2024)Full year 2025 results: EPS: AU$0.039 (up from AU$0.038 in FY 2024). Revenue: AU$14.1m (up 12% from FY 2024). Net income: AU$1.88m (up 2.4% from FY 2024). Profit margin: 13% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 24First half 2025 earnings released: EPS: AU$0.017 (vs AU$0.017 in 1H 2024)First half 2025 results: EPS: AU$0.017 (in line with 1H 2024). Revenue: AU$6.64m (up 3.7% from 1H 2024). Net income: AU$838.0k (flat on 1H 2024). Profit margin: 13% (in line with 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 21Full year 2024 earnings released: EPS: AU$0.038 (vs AU$0.029 in FY 2023)Full year 2024 results: EPS: AU$0.038 (up from AU$0.029 in FY 2023). Revenue: AU$12.6m (up 5.7% from FY 2023). Net income: AU$1.84m (up 31% from FY 2023). Profit margin: 15% (up from 12% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year.
Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0.014 (vs AU$0.016 in 1H 2022)First half 2023 results: EPS: AU$0.014 (down from AU$0.016 in 1H 2022). Revenue: AU$5.72m (down 1.7% from 1H 2022). Net income: AU$678.7k (down 13% from 1H 2022). Profit margin: 12% (down from 13% in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 150% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 26Full year 2022 earnings released: EPS: AU$0.028 (vs AU$0.014 in FY 2021)Full year 2022 results: EPS: AU$0.028 (up from AU$0.014 in FY 2021). Revenue: AU$11.8m (up 17% from FY 2021). Net income: AU$1.36m (up 109% from FY 2021). Profit margin: 12% (up from 6.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 136% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 18%After last week's 18% share price gain to AU$1.25, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 36x in the Life Sciences industry globally. Total returns to shareholders of 128% over the past three years.
分析記事 • Jun 01Cryosite (ASX:CTE) Ticks All The Boxes When It Comes To Earnings GrowthFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • Mar 03First half 2026 earnings released: EPS: AU$0.023 (vs AU$0.017 in 1H 2025)First half 2026 results: EPS: AU$0.023 (up from AU$0.017 in 1H 2025). Revenue: AU$8.27m (up 25% from 1H 2025). Net income: AU$1.14m (up 36% from 1H 2025). Profit margin: 14% (up from 13% in 1H 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year.
New Risk • Feb 28New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 114% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (114% net debt to equity). Market cap is less than US$100m (AU$58.8m market cap, or US$41.9m).
分析記事 • Feb 09Cryosite Limited's (ASX:CTE) Price Is Out Of Tune With EarningsWith a price-to-earnings (or "P/E") ratio of 31.2x Cryosite Limited ( ASX:CTE ) may be sending very bearish signals at...
Board Change • Jan 13No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Dec 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Oct 27Investor sentiment improves as stock rises 28%After last week's 28% share price gain to AU$1.30, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 36x in the Life Sciences industry globally. Total returns to shareholders of 125% over the past three years.
Board Change • Sep 18No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Aug 22Full year 2025 earnings released: EPS: AU$0.039 (vs AU$0.038 in FY 2024)Full year 2025 results: EPS: AU$0.039 (up from AU$0.038 in FY 2024). Revenue: AU$14.1m (up 12% from FY 2024). Net income: AU$1.88m (up 2.4% from FY 2024). Profit margin: 13% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
分析記事 • Aug 19Cryosite Limited's (ASX:CTE) Share Price Could Signal Some RiskASX:CTE 1 Year Share Price vs Fair Value Explore Cryosite's Fair Values from the Community and select yours It's not a...
お知らせ • Aug 18Cryosite Limited, Annual General Meeting, Oct 16, 2025Cryosite Limited, Annual General Meeting, Oct 16, 2025. Location: at the thomson geer offices, at level 23, rialto south tower, 525 collins street, melbourne vic 3004 Australia
Recent Insider Transactions • Jul 02Non-Executive Chairman recently bought AU$56k worth of stockOn the 27th of June, Mark Kerr bought around 75k shares on-market at roughly AU$0.74 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Mark's only on-market trade for the last 12 months.
Board Change • Jun 23No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Mar 17No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Feb 24First half 2025 earnings released: EPS: AU$0.017 (vs AU$0.017 in 1H 2024)First half 2025 results: EPS: AU$0.017 (in line with 1H 2024). Revenue: AU$6.64m (up 3.7% from 1H 2024). Net income: AU$838.0k (flat on 1H 2024). Profit margin: 13% (in line with 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jan 15Cryosite Limited's (ASX:CTE) Subdued P/E Might Signal An OpportunityThere wouldn't be many who think Cryosite Limited's ( ASX:CTE ) price-to-earnings (or "P/E") ratio of 19.1x is worth a...
お知らせ • Nov 22Cryosite Limited Announces Resignation of Michael Austin as Joint Company SecretaryCryosite Limited announced that Mr. Michael Austin has resigned as Joint Company Secretary, effective 22 November 2024. Mr. Hamish George of Bio101 Financial Advisory Pty Ltd. remains as Company Secretary and is responsible for communications with the ASX in relation to Listing Rule matters under ASX Listing Rule 12.6.
お知らせ • Oct 21Cryosite Limited, Annual General Meeting, Nov 22, 2024Cryosite Limited, Annual General Meeting, Nov 22, 2024. Location: boardroom, level 2 90 william st, melbourne,vic, 3000., melbourne, Australia
お知らせ • Sep 20Cryosite Limited Announces Company Secretary ChangesCryosite Limited announced that Hamish George and Michael Austin of Bio101 Financial Advisory Pty Ltd. (Bio101) have been appointed Joint Company Secretaries of the Company. The appointment follows the resignation of Mr. Dray Andrea as Company Secretary, effective 20 September 2024. The Board would like to thank Mr. Andrea for his service in the role of Company Secretary.
分析記事 • Aug 22Cryosite (ASX:CTE) Is Due To Pay A Dividend Of A$0.02Cryosite Limited ( ASX:CTE ) has announced that it will pay a dividend of A$0.02 per share on the 10th of October. This...
Declared Dividend • Aug 22Final dividend of AU$0.02 announcedShareholders will receive a dividend of AU$0.02. Ex-date: 6th September 2024 Payment date: 10th October 2024 Dividend yield will be 8.8%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 14% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • Aug 21Full year 2024 earnings released: EPS: AU$0.038 (vs AU$0.029 in FY 2023)Full year 2024 results: EPS: AU$0.038 (up from AU$0.029 in FY 2023). Revenue: AU$12.6m (up 5.7% from FY 2023). Net income: AU$1.84m (up 31% from FY 2023). Profit margin: 15% (up from 12% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year.
分析記事 • Aug 20With A 31% Price Drop For Cryosite Limited (ASX:CTE) You'll Still Get What You Pay ForCryosite Limited ( ASX:CTE ) shares have had a horrible month, losing 31% after a relatively good period beforehand...
お知らせ • Aug 20+ 2 more updatesCryosite Limited Announces Retirement of John Hogg as Chief Executive Officer, Effective October 31, 2024Cryosite announced the retirement of its Chief Executive Officer, Mr. John Hogg, with effect from October 31, 2024. The Board thanks Mr. Hogg for his support and service to the Board and the Company over his tenure.
Buy Or Sell Opportunity • Jul 26Now 20% undervaluedOver the last 90 days, the stock has risen 14% to AU$0.97. The fair value is estimated to be AU$1.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.5% over the last 3 years. Earnings per share has grown by 29%.
分析記事 • Jul 23Calculating The Intrinsic Value Of Cryosite Limited (ASX:CTE)Key Insights The projected fair value for Cryosite is AU$1.21 based on 2 Stage Free Cash Flow to Equity With AU$0.98...
New Risk • Jun 26New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: AU$8.2m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Significant insider selling over the past 3 months (AU$8.2m sold). Market cap is less than US$100m (AU$56.1m market cap, or US$37.5m).
お知らせ • Jun 25Cryosite Limited Announces Retirement of Andrew Kroger from the Board of DirectorsCryosite Limited announced that Andrew Kroger has retired from the board of directors (Board) effective from June 25, 2024.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 24%After last week's 24% share price gain to AU$1.05, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 32x in the Life Sciences industry globally. Total returns to shareholders of 238% over the past three years.
分析記事 • May 09Cryosite Limited's (ASX:CTE) 33% Jump Shows Its Popularity With InvestorsThe Cryosite Limited ( ASX:CTE ) share price has done very well over the last month, posting an excellent gain of 33...
Recent Insider Transactions • Apr 27Non Executive Director recently sold AU$830k worth of stockOn the 23rd of April, Andrew Kroger sold around 1m shares on-market at roughly AU$0.83 per share. This transaction amounted to 7.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • Feb 22Cryosite Limited Announces Board ChangesCryosite Limited announced the appointment of Mr. Andrew Kerr as a Director of the Company. Mr. John Hogg will step down as Managing Director and continue in his current executive position as CEO of Cryosite. Andrew is an experienced financial services professional in both the Australian and international markets. Andrew is a qualified Certified Practising Accountant (CPA) and a graduate of the Australian Institute of Company Directors (GAICD) course. Through his roles at Bank of America Merrill Lynch and Macquarie Bank, Andrew has obtained strong sustainability and ESG credentials which will greatly complement the Board.
Upcoming Dividend • Feb 14Upcoming dividend of AU$0.05 per share at 2.2% yieldEligible shareholders must have bought the stock before 21 February 2024. Payment date: 29 February 2024. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Australian dividend payers (6.5%). Higher than average of industry peers (0.5%).
分析記事 • Feb 02Subdued Growth No Barrier To Cryosite Limited's (ASX:CTE) PriceWhen close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...
Board Change • Dec 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Chairman Mark Kerr was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 08Cryosite Limited Announces Director ChangesCryosite Limited announced the appointment of Mr. Mark Kerr, as a new Director and Chairman. Mr. John Hogg, CEO of Cryosite will also join the Board as the Managing Director. The only variation to Mr. Hogg's employment agreement is to reflect his new office with the Company. The company announced the retirement from the Board of Directors of Steven Waller, Nicola Swift and Luis Antonio. The Board thanks the three retiring directors for their outstanding contribution to the Company over a number of years. The retiring directors have contributed substantial hours beyond what was expected to ensure the success of the Company going forward.
お知らせ • Oct 02Cryosite Limited, Annual General Meeting, Nov 23, 2023Cryosite Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time. Location: The offices of Cryosite, 13A Ferndell St, South Granville New South Wales Australia
Upcoming Dividend • Aug 31Upcoming dividend of AU$0.015 per share at 1.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 06 October 2023. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Australian dividend payers (7.0%). Higher than average of industry peers (0.5%).
お知らせ • Aug 25Cryosite Limited Announces Dividend for the Twelve Months Ended June 30, 2023, Payable on October 6, 2023Cryosite Limited announced dividend of AUD 0.01500000 per share for the twelve months ended June 30, 2023. Record date is September 8, 2023. Ex-date is September 7, 2023. Payment date is October 6, 2023.
Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0.014 (vs AU$0.016 in 1H 2022)First half 2023 results: EPS: AU$0.014 (down from AU$0.016 in 1H 2022). Revenue: AU$5.72m (down 1.7% from 1H 2022). Net income: AU$678.7k (down 13% from 1H 2022). Profit margin: 12% (down from 13% in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 150% per year, which means it is well ahead of earnings.
分析記事 • Feb 07Do Cryosite's (ASX:CTE) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
お知らせ • Jan 20Cryosite Limited Announces Change of Company SecretaryCryosite Limited announces the resignation of Kim Bradley-Ware and the appointment of Dray Andrea as Company Secretary, both effective January 18, 2023.
Recent Insider Transactions • Jan 18Insider recently bought AU$481k worth of stockOn the 13th of January, Mark Kerr bought around 650k shares on-market at roughly AU$0.74 per share. This transaction amounted to 39% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$582k. Insiders have collectively bought AU$2.6m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Dec 26Insider recently bought AU$582k worth of stockOn the 19th of December, Mark Kerr bought around 885k shares on-market at roughly AU$0.66 per share. This transaction amounted to 79% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$2.1m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Oct 14Insider recently bought AU$447k worth of stockOn the 11th of October, Mark Kerr bought around 600k shares on-market at roughly AU$0.74 per share. This transaction amounted to 63% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$1.6m more in shares than they have sold in the last 12 months.
お知らせ • Sep 21Cryosite Limited, Annual General Meeting, Nov 17, 2022Cryosite Limited, Annual General Meeting, Nov 17, 2022, at 10:00 E. Australia Standard Time. Location: at the offices of Stone & Chalk, Level 4, 11 York Street, Sydney NSW 2000 Sydney Nsw 2000 Australia
Upcoming Dividend • Sep 08Upcoming dividend of AU$0.01 per shareEligible shareholders must have bought the stock before 15 September 2022. Payment date: 14 October 2022. Trailing yield: 1.4%. Lower than top quartile of Australian dividend payers (6.6%). Higher than average of industry peers (0.4%).
お知らせ • Aug 26Cryosite Limited Announces Ordinary Dividend for the Year Ended June 30, 2022, Payable on October 14, 2022Cryosite Limited announced ordinary dividend of AUD 0.01000000 for the year ended June 30, 2022. Record Date is September 16, 2022. Ex Date is September 15, 2022. Payment Date is October 14, 2022.
Reported Earnings • Aug 26Full year 2022 earnings released: EPS: AU$0.028 (vs AU$0.014 in FY 2021)Full year 2022 results: EPS: AU$0.028 (up from AU$0.014 in FY 2021). Revenue: AU$11.8m (up 17% from FY 2021). Net income: AU$1.36m (up 109% from FY 2021). Profit margin: 12% (up from 6.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 136% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Aug 19Should You Be Adding Cryosite (ASX:CTE) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • May 02Do Cryosite's (ASX:CTE) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Nicola Swift was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Mar 03Non Executive Director recently bought AU$321k worth of stockOn the 28th of February, Andrew Kroger bought around 716k shares on-market at roughly AU$0.45 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$931k more in shares than they have sold in the last 12 months.
Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: AU$0.016 (up from AU$0.006 in 1H 2021). Revenue: AU$5.82m (up 19% from 1H 2021). Net income: AU$782.4k (up 175% from 1H 2021). Profit margin: 13% (up from 5.8% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 119% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions Derivative • Sep 09Key Executive exercised options to buy AU$546k worth of stock.On the 6th of September, Bryan Dulhunty exercised options to buy 1m shares at a strike price of around AU$0.06, costing a total of AU$78k. This transaction amounted to 4,333% of their direct individual holding at the time of the trade. Bryan currently holds less than 1% of total shares outstanding. Company insiders have collectively bought AU$687k more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Aug 26Full year 2021 earnings released: EPS AU$0.014 (vs AU$0.032 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: AU$10.1m (up 12% from FY 2020). Net income: AU$652.6k (down 56% from FY 2020). Profit margin: 6.5% (down from 17% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Jun 11Non Executive Director recently bought AU$170k worth of stockOn the 8th of June, Andrew Kroger bought around 473k shares on-market at roughly AU$0.36 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$173k more in shares than they have sold in the last 12 months.
Is New 90 Day High Low • Feb 17New 90-day low: AU$0.21The company is down 25% from its price of AU$0.28 on 18 November 2020. The Australian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period.
Is New 90 Day High Low • Dec 21New 90-day high: AU$0.36The company is up 59% from its price of AU$0.23 on 22 September 2020. The Australian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Nov 12New 90-day high: AU$0.30The company is up 76% from its price of AU$0.17 on 14 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.
お知らせ • Oct 15+ 1 more updateCryosite Limited Announces the Appointment of John Hogg as Chief Executive OfficerCryosite Limited announced the appointment of Mr. John Hogg as Chief Executive Officer of the Company commencing October 15, 2020. Mr. Hogg joined Cryosite in July 2018 and was promoted to General Manager of Operations on the December 1, 2019. He has deployed his skills and experience in Australia, Asia and the US. Mr. Hogg has qualifications in materials management, freight management, accounting and computing, including European Senior Logistician (ESLog) certification, and he is a Chartered Member of The Chartered Institute of Logistics and Transport (CMILT).
Is New 90 Day High Low • Oct 08New 90-day high: AU$0.24The company is up 71% from its price of AU$0.14 on 10 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Sep 18New 90-day high: AU$0.21The company is up 65% from its price of AU$0.13 on 18 June 2020. The Australian market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 11% over the same period.